Biomerica’s Aware® Breast Self Exam and EZ Detect™ Colon Disease Test Now Available on Amazon and Fulfilled by Amazon
September 29 2022 - 8:19AM
Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that
the Company’s Aware® Breast Self Exam device and EZ Detect Colon
Disease test are now being sold on Amazon and fulfilled by Amazon.
Aware:
https://www.amazon.com/gp/product/B010OVMR2S/ref=ewc_pr_img_1?smid=A12JU5SP5PIFD3&psc=1
EZ Detect:
https://www.amazon.com/gp/product/B00EF2BPZ8/ref=ewc_pr_img_1?smid=A12JU5SP5PIFD3&psc=1
The Biomerica FDA-cleared Aware® Breast Self
Exam device is a revolutionary way for women to enhance tactile
sensitivity to changes or irregularities in breast tissue, making
breast self-exams easy and convenient. The Aware® device can
facilitate an effective self-exam and can serve as a reminder to
perform a breast self-exam every month.
Breast Cancer is the most common cancer among
women. Unfortunately, every woman is potentially at risk, as more
than 70% of women diagnosed have no family history of breast
cancer. Early detection significantly improves the chances that
breast cancer can be diagnosed and treated successfully. Survival
rates are as high as 99% when the cancer is found early while still
localized in the breast. However, if the cancer has spread to the
regional lymph nodes, the 5-year survival rate falls to
86%[1,2]. About 80% of breast cancer cases are detected
because women themselves notice changes in their breast[3]. This
highlights the important role that each woman can play in managing
their own health. However, a breast self-examination is not a
replacement for regular medical visits and periodic ultrasound or
mammography. All three steps are important to finding breast cancer
early. The relevance of early detection cannot be
overemphasized.
The Biomerica EZ Detect™ Colon Disease Test is
the simplest in-home, two-minute diagnostic test to detect hidden
blood in the stool, one of the primary early warning signs of
colorectal disease. The test does not require handling of stool or
dietary restrictions.
Colorectal cancer (“CRC”) is the second most
common cause of cancer death in the United States. In 2020, an
estimated 147,950 individuals would be diagnosed with CRC and an
estimated 53,200 would die from the disease, including 17,930 cases
and 3,640 deaths in individuals under the age of 50[4].
In a study performed by Johns Hopkins
University, EZ Detect™ was preferred 10:1 by patients over another
fecal occult blood test. Published studies have also indicated that
the best colorectal screening test is “the one that gets done.”[5]
With EZ Detect, the user simply drops a test pad onto the surface
of the water in the toilet bowl after a bowel movement. If blood is
present in the person’s stool, a blue-green indicator will appear
on the test pad within two minutes. The pad is then simply flushed
down the toilet. Other colorectal screening tests require
collecting a stool sample and mailing it to a lab for processing.
Requiring a patient to collect and mail a stool sample results in a
high percentage of these competing tests never being performed by
patients[6]. EZ Detect is simple to perform and provides results in
just two minutes.
Zack Irani, Chief Executive Officer of
Biomerica, commented, “The key to better outcomes in all cancers is
early detection and regular screening. Both Aware and EZ Detect are
inexpensive and easy to use. Both can be performed in the privacy
of one’s home. I’m proud of the work we do to produce products that
help save lives and improve the health of people.”
For further information about the Aware® Breast
Self Exam Product and the EZ Detect Colon Disease test, please
visit https://AwareBSE.com and https://ezdetect.com
About Biomerica (NASDAQ:
BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical
technology company that develops, patents, manufactures and markets
advanced diagnostic and therapeutic products used at the point of
care (in home and in physicians’ offices) and in hospital/clinical
laboratories for detection and/or treatment of medical conditions
and diseases. The Company’s products are designed to enhance the
health and well-being of people, while reducing total healthcare
costs. Biomerica’s primarily focus is on gastrointestinal and
inflammatory diseases where the Company has multiple diagnostic and
therapeutic products in development.
1.
https://www.webmd.com/breast-cancer/guide/breast-cancer-survival-rates.
Accessed 08 July 2022 2.
https://www.cancer.net/cancer-types/breast-cancer/statistics.
Accessed 08 July 20223.
https://www.pinkribbon-deutschland.de/vorsorge-fakten/fakten,
accessed 02 AUG 2022 4. Siegel, R.L., et al., Colorectal
cancer statistics, 2020. CA Cancer J Clin, 2020. 70(3): p.
145-164.5. Lansdorp-Vogelaar, I., A.B. Knudsen, and H.
Brenner, Cost-effectiveness of colorectal cancer screening - an
overview. Best Pract Res Clin Gastroenterol, 2010. 24(4): p.
439-49.6. Navarro, M., et al., Colorectal cancer population
screening programs worldwide in 2016: An update. World J
Gastroenterol, 2017. 23(20): p. 3632-3642.
The Private Securities Litigation Reform Act of 1995 provides a
"safe harbor" for forward-looking statements. Certain information
included in this press release (as well as information included in
oral statements or other written statements made or to be made by
Biomerica) contains statements that are forward-looking, such as
statements relating to the efficacy of the Company’s Aware® Breast
Self-Exam device, EZ Detect® test and other tests and product, FDA
clearance of these tests and product, possible online and/or
in-store offering and sale of the Aware® Breast Self-Exam device
and EZ Detect® test at Walmart, Amazon or other potential
distributors and retailers, the rapidity of testing results,
negotiations with international distribution partners, uniqueness
of the Company’s tests and products, test result accuracy of
products, the ability of the Aware® device to improve the detection
of breast abnormalities, pricing of the Company’s test kits,
domestic or international demand for these tests and product ,
potential revenues from the sale of current or future products, and
patent protection on any of the Company’s products or technologies.
Such forward-looking information involves important risks and
uncertainties that could significantly affect anticipated results
in the future, including, without limitation: results of studies
testing the efficacy of the Company’s tests and other products;
regulatory approvals necessary prior to commercialization any of
the Company’s products; availability of the Company’s test kits and
other products; capacity, resource and other constraints on our
suppliers; dependence on our third party manufacturers; dependence
on international shipping carriers; governmental import/export
regulations; demand for our various tests and other products;
competition from other similar products and from competitors that
have significantly more financial and other resources available to
them; governmental virus control regulations that make it difficult
or impossible for the company to maintain current operations; the
Company’s ability to comply with current and future regulations in
the countries where our products are made and sold and the
Company’s ability to obtain patent protection on any aspects of its
rapid test technologies. Accordingly, such results may differ
materially from those expressed in any forward-looking statements
made by or on behalf of Biomerica. Additionally, potential risks
and uncertainties include, among others, fluctuations in the
Company's operating results due to its business model and expansion
plans, downturns in international and or national economies, the
Company's ability to raise additional capital, the competitive
environment in which the Company will be competing, and the
Company's dependence on strategic relationships. The Company is
under no obligation to update any forward-looking statements after
the date of this release.
Corporate Contact:
Zack IraniCEO949-642-2111Zirani@biomerica.com
Source: Biomerica, Inc.
Biomerica (NASDAQ:BMRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biomerica (NASDAQ:BMRA)
Historical Stock Chart
From Apr 2023 to Apr 2024